Asset profile

PL2000 · Palatin Technologies, Inc. (PTN)

Indication
rare neuroendocrine obesity disorders (hypothalamic obesity, Prader-Willi syndrome, Bardet-Biedl syndrome)
CompanyPTNPalatin Technologies, Inc.

Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. Its product candidates are targeted, receptor-specific therapeutics for the tre…

On the calendar

Timeline

Newest first.

Nov 17, 2026
12:30 PM
PTNPalatin Technologies, Inc.

Palatin Advances PL2000 MC4R Agonist to Phase 1 in H1 2027

More from Palatin Technologies, Inc.

Other drugs and candidates from the same company tracked in this sector.

PL2000 · Palatin Technologies, Inc. (PTN) — FDA Timeline & Readiness Checklist | SimianX AI